Design and Computational Analysis of an MMP9 Inhibitor in Hypoxia-Induced Glioblastoma Multiforme
ACS Omega · 21.03.2023 · 8 (11) · 10565-10590
DOI: 10.1021/acsomega.3c00441 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 13.03.2023. Verfasst von Smita Kumari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Delhi 110042, …. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Delhi Technological University, Department of Biotechnology , Ministry of Science and Technology.
Abstract (Originalsprache)
The main therapeutic difficulties in treating hypoxia-induced glioblastoma multiforme (GBM) are toxicity of current treatments and the resistance brought on by the microenvironment. More effective therapeutic alternatives are urgently needed to reduce tumor lethality. Hence, we screened plant-based natural product panels intending to identify novel drugs without elevating drug resistance. We explored GEO for the hypoxia GBM model and compared hypoxic genes to non-neoplastic brain cells. A total of 2429 differentially expressed genes expressed exclusively in hypoxia were identified. The functional enrichment analysis demonstrated genes associated with GBM, further PPI network was constructed, and biological pathways associated with them were explored. Seven webtools, including GEPIA2.0, TIMER2.0, TCGA-GBM, and GlioVis, were used to validate 32 hub genes discovered using Cytoscape tool in GBM patient samples. Four GBM-specific hypoxic hub genes, LYN, MMP9, PSMB9, and TIMP1, were connected to the tumor microenvironment using TIMER analysis. 11 promising hits demonstrated positive drug-likeness with nontoxic characteristics and successfully crossed blood-brain barrier and ADMET analyses. Top-ranking hits have stable intermolecular interactions with the MMP9 protein according to molecular docking, MD simulation, MM-PBSA, PCA, and DCCM analyses. Herein, we have reported flavonoids, 7,4'-dihydroxyflavan, (3R)-3-(4-hydroxybenzyl)-6-hydroxy-8-methoxy-3,4-dihydro-2H-1-benzopyran, and 4'-hydroxy-7-methoxyflavan, to inhibit MMP9, a novel hypoxia gene signature that could serve as a promising predictor in various clinical applications, including GBM diagnosis, prognosis, and targeted therapy.
Autor:innen und Institutionen
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Delhi 110042, India.
ORCID-Profile: Pravir Kumar
Förderung
- Delhi Technological University
- Department of Biotechnology , Ministry of Science and Technology
Zitieren
APA
Kumari, S., & Kumar, P. (2023). Design and Computational Analysis of an MMP9 Inhibitor in Hypoxia-Induced Glioblastoma Multiforme. ACS Omega, 8(11), 10565-10590. https://doi.org/10.1021/acsomega.3c00441
Vancouver
Kumari S, Kumar P. Design and Computational Analysis of an MMP9 Inhibitor in Hypoxia-Induced Glioblastoma Multiforme. ACS Omega. 2023;8(11):10565-10590. doi:10.1021/acsomega.3c00441
BibTeX
@article{Kumari2023,
author = {Kumari, Smita and Kumar, Pravir},
title = {Design and Computational Analysis of an MMP9 Inhibitor in Hypoxia-Induced Glioblastoma Multiforme},
journal = {ACS Omega},
year = {2023},
volume = {8},
number = {11},
pages = {10565--10590},
doi = {10.1021/acsomega.3c00441}
}
EUVIMED